Nazanin Mirshahi

The Virginia Biosciences Commercialization Center (VBCC) develops and leads implementation of tailored commercialization strategies for later-stage bioscience companies looking to launch their product(s) in U.S. markets. This comprehensive program surrounds each company with scientific, clinical and industry experts focused on every facet of the commercialization process, assuring effective scale-up and maximization of enterprise value. Virginia Life Sciences Investments (VLSI), the Commercialization Center's parent company, can provide financial support for realization of significant commercialization milestones. VLSI's primary focus is on medical device and diagnostic companies that provide a significantly more effective and cost-efficient solution to the market.